Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes

Rhea-AI Filing Summary

Bioventus Inc. SVP & CFO Mark Leonard Singleton reported routine equity compensation activity in the form of restricted stock units. On March 20, 2026, he exercised 18,625 RSUs, receiving the same number of shares of Class A common stock at a stated price of $0.00 per share.

To cover tax obligations related to this vesting, 8,091 shares of Class A common stock were withheld at $8.64 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, Singleton directly held 169,981 shares of Class A common stock.

Insider Trade Summary

18,625 shares exercised/converted

Mixed 3 txns

Insider Singleton Mark Leonard

Role SVP & CFO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	18,625	$0.00	--
Exercise	Class A Common Stock	18,625	$0.00	--
Tax Withholding	Class A Common Stock	8,091	$8.64	$70K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Class A Common Stock — 178,072 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. The original grant of 74,500 RSUs vested in four approximately equal annual installments that began on March 21, 2023.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singleton Mark Leonard

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/20/2026		M		18,625	A	$0	178,072	D
Class A Common Stock	03/20/2026		F		8,091	D	$8.64	169,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/20/2026		M			18,625	(2)	(2)	Class A Common Stock	18,625	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The original grant of 74,500 RSUs vested in four approximately equal annual installments that began on March 21, 2023.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Bioventus (BVS) SVP & CFO report?

Bioventus SVP & CFO Mark Leonard Singleton reported exercising 18,625 restricted stock units into Class A common shares. The filing also shows a related tax-withholding disposition, reflecting routine equity compensation activity rather than an open-market stock trade.

How many Bioventus (BVS) shares did the CFO acquire in this Form 4?

The CFO acquired 18,625 shares of Bioventus Class A common stock through the exercise of restricted stock units. Each RSU converted into one share, consistent with the grant’s terms and its scheduled multi-year vesting structure described in the accompanying footnotes.

Why were 8,091 Bioventus (BVS) shares classified as a tax-withholding disposition?

8,091 shares were withheld to satisfy tax obligations arising from the RSU vesting, at $8.64 per share. This is coded as a tax-withholding disposition (transaction code F), meaning shares were delivered for taxes rather than sold in the open market.

How many Bioventus (BVS) shares does the CFO hold after these transactions?

Following the RSU exercise and tax-withholding disposition, the CFO directly holds 169,981 shares of Bioventus Class A common stock. This figure reflects his updated ownership position after converting vested RSUs and delivering some shares to cover tax liabilities.

What do the RSU footnotes in the Bioventus (BVS) Form 4 explain?

The footnotes explain that each RSU represents a contingent right to one Class A common share, and that the original 74,500-unit grant vests in four roughly equal annual installments beginning March 21, 2023, clarifying the scheduled nature of this 18,625-unit vesting.

Does this Bioventus (BVS) Form 4 show any open-market stock sales by the CFO?

The Form 4 does not show open-market sales; it reports RSU exercise and a tax-withholding disposition. The tax-related share delivery is different from discretionary selling, as it occurs to satisfy obligations linked to the equity award vesting event.